HER2 overexpression, found in 15–30 % of human breast cancers, and estrogen receptor-α, positive in 70 % of breast cancers, also increase HIF-α levels via increased PI3K/Akt/mTOR signaling. Here, ERBB2 is linked to breast carcinoma.